Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

No abstract is available for this paper.

• Publication year

  2016

• Venue

  British Journal of Dermatology

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjd.14528PMID 26959083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic innovations in inflammatory bowel diseases

  2016cited by this paper
• Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study.

  2015cited by this paper
• Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study.

  2015cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials

  2015cited by this paper
• Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink

  2015cited by this paper
• The Danish Civil Registration System as a tool in epidemiology

  2014cited by this paper
• Psoriasis and smoking: a systematic review and meta‐analysis

  2014cited by this paper
• JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

  2014cited by this paper
• Correlations between Psoriasis and Inflammatory Bowel Diseases

  2013cited by this paper
• JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

  2012cited by this paper
• The association of psoriasis with autoimmune diseases.

  2012cited by this paper
• Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

  2012cited by this paper
• Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women

  2012cited by this paper
• DIFFERENTIAL REGULATION OF INTERLEUKIN-17 AND INTERFERON- PRODUCTION IN INFLAMMATORY BOWEL DISEASE

  2011cited by this paper
• Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan.

  2011cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

  2011cited by this paper
• Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study

  2011cited by this paper
• Danish registers on personal income and transfer payments

  2011cited by this paper
• Smoking, Physical Activity, Nutrition and Lifestyle: Environmental Factors and Their Impact on IBD

  2010cited by this paper
• Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.

  2010cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2009cited by this paper
• Psoriasis associated with ulcerative colitis and Crohn's disease

  2009cited by this paper
• Inflammatory bowel disease.

  2009cited by this paper
• Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis

  2009cited by this paper
• Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease

  2009cited by this paper
• The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

  2009cited by this paper
• The genetics and immunopathogenesis of inflammatory bowel disease

  2008cited by this paper
• Th17 cells in human disease

  2008cited by this paper
• A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.

  2007cited by this paper
• Genome-Wide Association

  2007cited by this paper
• Pathogenesis and clinical features of psoriasis.

  2007cited by this paper
• Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

  2007cited by this paper
• A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

  2006cited by this paper
• Signal Transducers and Activators of Transcription 3 Signaling Pathway: An Essential Mediator of Inflammatory Bowel Disease and Other Forms of Intestinal Inflammation

  2005cited by this paper
• The Danish National Hospital Register. A valuable source of data for modern health sciences.

  1999cited by this paper
• The Danish prescription registries.

  1997cited by this paper
• Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system.

  1996cited by this paper
• Increased occurrence of psoriasis in patients with Crohn's disease and their relatives.

  1990cited by this paper
• Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis

  1982cited by this paper
• Clinical, Cosmetic and Investigational Dermatology Dovepress Psoriasis and Comorbidities: Links and Risks

  year unknowncited by this paper

• Circulating metabolites mediating the effect of psoriatic arthritis on Crohn disease risk: A mediation Mendelian randomization study

  2026cites this paper
• Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease

  2025cites this paper
• Psychiatric Comorbidities in Patients with Psoriasis: A 10-Year Retrospective Epidemiological Study from a Tertiary University Center in Northeastern Romania

  2025cites this paper
• Shared genetic architecture between psoriasis and immune-mediated gastrointestinal diseases: a study based on cross-trait GWAS and pleiotropy analysis

  2025influential citation
• Integrating clinical challenges and nanotechnological based approaches for psoriasis therapy.

  2025cites this paper
• Dysbiosis of the Saliva Microbiota in Patients with Psoriasis: A Case-Control Study

  2025cites this paper
• Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

  2025cites this paper
• Psychiatric Adverse Effects of Biologic and Novel Systemic Agents for Psoriasis and Inflammatory Bowel Disease: A Case Series and Literature Review.

  2025cites this paper
• Psoriasis as a Potential Risk Factor for Inflammatory Bowel Disease: Findings from a Nationally Representative Korean Population

  2025influential citation
• Inflammatory bowel disease–dermatology: evaluation of a collaborative, multidisciplinary, patient-centred care model

  2025cites this paper
• Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition

  2025cites this paper
• Uncovering common disease mechanisms and critical biomarkers in Crohn’s disease with concurrent psoriasis and exploring potential therapeutic agents

  2025cites this paper
• Practical Considerations for the Treatment of Patients with Psoriatic Arthritis and Comorbid Inflammatory Bowel Disease.

  2025cites this paper
• The relationship between biological aging and psoriasis: evidence from three observational studies

  2025cites this paper
• Identification and validation of shared biomarkers and drug repurposing in psoriasis and Crohn’s disease: integrating bioinformatics, machine learning, and experimental approaches

  2025cites this paper
• The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis

  2024cites this paper
• Clinical phenotypes and therapeutic outcomes in enteropathic arthritis: a multivariate analysis from a retrospective cohort.

  2024cites this paper
• Coexisting autoimmune disorders among patients with inflammatory bowel disease at a tertiary center in Saudi Arabia: A cross-sectional study

  2024cites this paper
• Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies

  2024cites this paper
• Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations

  2024cites this paper
• Identification of Potential Ferroptosis Biomarkers and Analysis of Immune Cell Infiltration in Psoriasis Using Machine Learning

  2024cites this paper
• A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State

  2024cites this paper
• Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

  2024influential citation
• Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study

  2024cites this paper
• Dermatologic manifestations in pediatric patients with inflammatory bowel disease

  2024cites this paper
• A Novel Multi-Strain E3 Probiotic Formula Improved the Gastrointestinal Symptoms and Quality of Life in Chinese Psoriasis Patients

  2024cites this paper
• Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

  2023cites this paper
• Integrated analysis of Mendelian Randomization and Bayesian colocalization reveals bidirectional causal association between inflammatory bowel disease and psoriasis

  2023cites this paper
• Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis.

  2023cites this paper
• Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials.

  2023influential citation
• Exploring comorbidity and pharmacological treatment patterns in psoriasis - a retrospective population-based cross-sectional study

  2023cites this paper
• Risk of incident autoimmune diseases in patients with newly diagnosed psoriatic disease: a nationwide population-based study

  2023cites this paper
• The link between psoriasis and other diseases based on epidemiological and genetic analyses

  2023cites this paper
• Clinical guidelines. Crohn’s disease (К50), adults

  2023cites this paper
• [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2----Management of Special Populations, Patients With Comorbid Conditions, and Risk

  2023cites this paper
• Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register

  2023cites this paper
• Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors

  2023cites this paper
• Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials

  2022cites this paper
• New onset severe ulcerative colitis following Ixekizumab therapy

  2022cites this paper
• Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review

  2022cites this paper
• Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study.

  2022cites this paper
• Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics

  2022cites this paper
• Sex- and gender-related differences in psoriatic arthritis

  2022cites this paper
• Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations

  2022cites this paper
• Psoriasis, inflammatory bowel disease, and uveitis as paradoxical adverse effects induced by TNF inhibitors in patients with immune-inflammatory rheumatic conditions

  2022cites this paper
• Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.

  2022cites this paper
• Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study *

  2022cites this paper
• PTT_A_328572 139..150

  2022cites this paper
• Comorbidity in Adult Psoriasis: Considerations for the Clinician

  2022cites this paper
• Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

  2022cites this paper
• Causal links between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional two-sample Mendelian randomization study

  2022cites this paper
• Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.

  2022cites this paper
• Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

  2022cites this paper
• Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark

  2022cites this paper
• Choosing the right biologic for complications of inflammatory bowel disease

  2022cites this paper
• Bidirectional association between psoriasis and inflammatory bowel disease in a paediatric population: a nationwide study in South Korea

  2022cites this paper
• Guidelines for Management of Psoriasis

  2021cites this paper
• Immune responses and therapeutic options in psoriasis

  2021cites this paper
• IL‐17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase

  2021cites this paper
• Incidence of Psoriasis in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Matched Cohort Study

  2021cites this paper
• Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib

  2021cites this paper
• The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.

  2021cites this paper
• The Psoriasis Decision Tree.

  2021cites this paper
• Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis

  2021cites this paper
• Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function

  2021cites this paper
• [Algorithms to identify chronic inflammatory rheumatism and psoriasis in medico-administrative databases: A review of the literature].

  2021cites this paper
• Microscopic colitis in Denmark: regional variations in risk factors and frequency of endoscopic procedures.

  2021cites this paper
• The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence

  2021cites this paper
• Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk

  2021cites this paper
• Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis

  2021cites this paper
• Ixekizumab

  2020cites this paper
• Microbiota-Dependent Effects of IL-22

  2020cites this paper
• Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases

  2020cites this paper
• Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

  2020cites this paper
• Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study

  2020cites this paper
• Adalimumab for Psoriasis

  2020cites this paper
• Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

  2020cites this paper
• Association of Psoriasis with Autoimmune Disorders: Results of a Pilot Study

  2020cites this paper
• Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23

  2020cites this paper
• Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis.

  2020cites this paper
• Coexisting psoriasis is associated with an increased risk of hospitalization for patients with inflammatory bowel disease: an analysis of the National Inpatient Sample database

  2020cites this paper
• Coping with Psoriasis or Hidradenitis Suppurativa: A Qualitative Study

  2020cites this paper
• Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

  2020influential citation
• Comorbidities, socioeconomic status, drug use, and health care consumption in Danish women with psoriasis: A nationwide cross-sectional study

  2020cites this paper
• Skin and Gut Microbiota in Psoriasis: A Systematic Review

  2020cites this paper
• Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study

  2020cites this paper
• Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials

  2020cites this paper
• Cardiovascular outcomes and extra-articular manifestations in patients with spondyloarthritis

  2020cites this paper
• Challenges in the clinical diagnosis of psoriatic arthritis.

  2020cites this paper
• Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

  2019cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management

  2019cites this paper
• Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

  2019cites this paper
• Socioeconomic Costs and Health Inequalities from Psoriasis: A Cohort Study

  2019cites this paper
• Management of psoriasis as a systemic disease: what is the evidence?

  2019cites this paper
• Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report

  2019cites this paper
• Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis

  2019cites this paper
• Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study.

  2019cites this paper
• Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris

  2019influential citation
• Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

  2019cites this paper
• Biologics for the primary care physician: Review and treatment of psoriasis.

  2019cites this paper